Market Overview

BeiGene to Present at the Morgan Stanley 16th Annual Global Healthcare Conference

Share:

CAMBRIDGE, Mass., and BEIJING, China, Sept. 04, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the Morgan Stanley 16th Annual Global Healthcare Conference in New York, NY. The presentation is scheduled for 11:40 AM ET on Wednesday, September 12, 2018.

A live webcast can be accessed from the investors section of BeiGene's website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.

About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,300 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.i  

Investor Contact                                         
Craig West                                               
+1 857-302-5189                                         
ir@beigene.com             

Media Contact
Liza Heapes
+ 1 857-302-5663
media@beigene.com                            

i ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.


 

logo 20171213_3.jpg

View Comments and Join the Discussion!